tiprankstipranks
Trending News
More News >
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Advertisement

Enlivex (ENLV) AI Stock Analysis

Compare
430 Followers

Top Page

ENLV

Enlivex

(NASDAQ:ENLV)

Rating:36Underperform
Price Target:
Enlivex's financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
Positive Factors
Efficacy Data
Enlivex has reported positive interim efficacy data for patients in Phase 1 with significant improvements and no safety issues.
Intellectual Property
Chinese patent claims allowed for Allocetra in osteoarthritis treatment, providing added protection through at least 2040.
Negative Factors
Clinical Trial
The Phase 2 trial will rigorously evaluate joint-pain and function with a double-blind, randomized, placebo-controlled design.

Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)

Enlivex Business Overview & Revenue Model

Company DescriptionEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
How the Company Makes MoneyEnlivex generates revenue primarily through collaborations, partnerships, and licensing agreements related to its proprietary immunotherapy technologies. As a clinical-stage company, it does not yet have commercialized products generating direct sales revenue. Instead, its financial income is heavily reliant on funding from research grants, strategic alliances with pharmaceutical companies, and potential milestone payments or royalties from future successful commercialization of its therapies. Significant partnerships with established healthcare and pharmaceutical firms may also contribute to its earnings by providing financial support for clinical trials and research activities.

Enlivex Financial Statement Overview

Summary
Enlivex is facing challenges typical of early-stage biotechnology firms, with no revenue and ongoing losses. The firm needs to address its lack of revenue generation and improve cash flow management to ensure its financial viability. While the low debt offers some flexibility, the continuous cash burn and equity decline may limit future strategic options.
Income Statement
15
Very Negative
Enlivex has faced significant operational challenges with no reported revenue in recent periods, leading to negative gross and net margins. The consistent negative EBIT and EBITDA margins highlight ongoing profitability issues, with a lack of revenue growth exacerbating the financial strain.
Balance Sheet
40
Negative
The balance sheet reflects a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's equity position has weakened over time as liabilities approach total assets, reducing the equity ratio. The declining stockholders' equity is a concern for financial stability.
Cash Flow
25
Negative
Cash flow analysis reveals negative operating and free cash flows, indicating operational inefficiencies and cash burn. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow from operations, posing a risk to long-term sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.002.28M
Gross Profit-545.00K-835.00K-777.00K-546.00K-286.00K
EBITDA-14.47M-28.22M-25.02M-18.74M-9.50M
Net Income-15.01M-29.07M-31.06M-14.47M-11.82M
Balance Sheet
Total Assets27.69M36.83M67.64M95.15M40.36M
Cash, Cash Equivalents and Short-Term Investments23.61M27.32M48.12M84.13M35.71M
Total Debt534.00K1.03M4.85M617.00K203.00K
Total Liabilities4.10M6.75M10.80M10.11M4.87M
Stockholders Equity23.59M30.08M56.84M85.04M35.49M
Cash Flow
Free Cash Flow-13.11M-23.76M-32.08M-19.17M-12.03M
Operating Cash Flow-13.01M-23.52M-23.95M-17.54M-11.01M
Investing Cash Flow9.06M-25.97M62.52M-38.41M-20.98M
Financing Cash Flow6.45M360.00K150.00K60.98M33.08M

Enlivex Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.17
Price Trends
50DMA
1.08
Positive
100DMA
1.05
Positive
200DMA
1.14
Positive
Market Momentum
MACD
0.04
Positive
RSI
52.00
Neutral
STOCH
14.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Positive. The current price of 1.17 is below the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.08, and above the 200-day MA of 1.14, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.00 is Neutral, neither overbought nor oversold. The STOCH value of 14.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENLV.

Enlivex Risk Analysis

Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enlivex Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$77.80M-121.65%-0.71%-169.29%
53
Neutral
$47.57M-36.31%15.73%51.00%
53
Neutral
$21.99M-93.19%6.96%32.32%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
36
Underperform
$28.14M-60.35%53.95%
27
Underperform
$42.91M-238.64%30.96%
$57.27M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ENLV
Enlivex
1.17
-0.19
-13.97%
CVM
Cel-Sci
6.29
-33.01
-83.99%
PULM
Pulmatrix
6.02
3.92
186.67%
OVID
Ovid Therapeutics
0.70
-0.36
-33.96%
IPA
ImmunoPrecise Antibodies
1.82
0.96
111.63%
JUNS
Jupiter Neurosciences, Inc.
1.73
-3.81
-68.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 24, 2025